Lanthanum Viatris

Lanthanum, the active ingredient in Lanthanum Viatris, is a phosphate binder presented as an oral tablet for oral use. It binds dietary phosphate in the gastrointestinal tract, reducing absorption and helping to lower serum phosphate levels in patients with chronic kidney disease who often develop hyperphosphatemia.

GNH USA supplies Lanthanum Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, dialysis units and community pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved documentation to facilitate import and distribution across EU and other markets.

Lanthanum Viatris is used as a phosphate binder to manage elevated serum phosphate in chronic kidney disease. - Hyperphosphatemia in chronic kidney disease: lowers serum phosphate levels by binding dietary phosphate. - Patients on dialysis with hyperphosphatemia: helps maintain target phosphate concentrations. - Renal transplant recipients with elevated phosphate: assists in controlling phosphate balance.

Lanthanum Viatris may cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Constipation - Abdominal discomfort - Flatulence - Metallic taste

Serious or Rare Side Effects: - Severe constipation or intestinal obstruction - Hypophosphatemia - Allergic reactions such as rash or anaphylaxis

When prescribing Lanthanum Viatris, several precautions should be observed. - Monitor serum phosphate: adjust dose based on regular laboratory values. - Assess calcium balance: avoid concurrent high calcium intake. - Evaluate gastrointestinal health: caution in patients with existing bowel disorders. - Adjust dose in renal impairment: follow prescriber guidance. - Avoid in known lanthanum hypersensitivity: discontinue if reaction occurs. - Store at room temperature: keep in original container, protect from moisture and heat.

Lanthanum Viatris can interact with other oral medications, requiring careful management.

Major Interactions (Avoid): - Tetracycline antibiotics: lanthanum binds and reduces absorption. - Iron supplements: concurrent use may markedly decrease lanthanum efficacy. - Levothyroxine: co‑administration can lower thyroid hormone absorption.

Moderate Interactions (Monitor Closely): - Calcium carbonate and other phosphate binders: may compete for binding sites. - Vitamin D analogues: monitor calcium‑phosphate product. - Bisphosphonates: separate dosing times to avoid reduced absorption.